Join Our Crew

Associate Scientist / Scientist, Molecular Biology

Philadelphia, PA

About the Position

Reporting to the Senior Director Gene Transfer Technologies, the Associate Scientist/Scientist, Molecular Biology will perform tasks aimed at generating genetic constructs to be used for advanced manufacturing of next generation cell therapies. The ideal candidate will be well versed in most current cloning technologies and perform multi-step procedures under limited technical supervision. Prior exposure to molecular cloning procedures related to gene editing and transposon-mediated gene transfer is beneficial. The position offers growth potential due to the rapid increase in new gene transfer technologies and the addition of new pipeline products.

Responsibilities Include

  • Using dedicated software, assemble genetic constructs in silico prior to laboratory work
  • Assemble genetic constructs using methods such as: restriction digests, TA TOPO cloning, site directed mutagenesis
  • Perform quality control analysis on assembled constructs prior to transitioning into cell culture
  • Support the tech transfer of new gene transfer methodologies from outside collaborators
  • Help establish molecular biology workflows for new gene transfer technologies
  • Maintain highest level of integrity and awareness in handling critical QC and molecular design work
  • Actively contribute to molecular biology process improvements and help implement new techniques and innovative trends
  • Perform lab associated tasks in accordance with cGLP and Cabaletta Bio lab safety policies
  • Maintain accurate and well-organized records and electronic laboratory notebook

Required Qualifications

  • Minimum of BS with 3 - 5 years of experience or MS degree with 1 - 2 years of experience in molecular biology, with overall 2 years of direct molecular cloning experience required. Seniority will be determined by individual’s specific experience.
  • Proficient understanding of Molecular Biology workflows with hands on experience with every step of a typical cloning procedure including analytics
  • Extensive experience with bacterial culture, such as screening and expanding clones, large scale plasmid preparations and cryopreservation of clones
  • Must be familiar with QC workflow for molecular constructs including sequencing, sequence data analysis and verification using dedicated software
  • Experience with all PCR methodologies such as PCR, qPCR, RT-qPCR, dPCR, ddPCR
  • Experience working with external CROs and academic collaborators preferred.
  • Experience in a startup industrial setting highly desirable
  • Must be highly organized and able to work independently
  • Must be able to clearly communicate in writing, must have a desire to be part of a growing organization that uses cutting-edge science
  • Exemplify a high level of flexibility to support various other activities as is typically asked for in the ability to learn new techniques outside of existing field of expertise. 

How to Apply

Please email directly to submit an application.

Please include your CV along with the title of the position you are applying for.


Our most important asset is our people and we offer competitive benefits including health and retirement, PTO, and stock option plans.

Equal Opportunity Employer

Cabaletta Bio is an equal opportunity employer. We do not discriminate on the basis of race, color, gender, gender identity, sexual orientation, age, religion, national or ethnic origin, disability, protected veteran status or any other basis protected by applicable law.

About Cabaletta Bio

Cabaletta Bio (NASDAQ: CABA) is focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases. Our proprietary technology utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to precisely bind and destroy only specific autoantibody-expressing B cells while sparing normal antibody-expressing B cells, which are essential for human health. Cabaletta’s Approach for selective B cell Ablation platform, called our CABA™ platform, has applicability across more than two dozen B cell-mediated autoimmune diseases that we have identified, reviewed and prioritized. CAAR T technology is based on the revolutionary Chimeric Antigen Receptor (CAR) T cell technology developed at the University of Pennsylvania that resulted in one of the first commercially-available CAR T cell products for the treatment of B cell malignancies. Cabaletta has an exclusive global licensing agreement and multiple sponsored research agreements with the University of Pennsylvania to develop CAAR T technology to treat B cell-mediated autoimmune diseases.

The Company’s lead product candidate, DSG3-CAART, received IND clearance from the FDA in September 2019, and initial safety data in clinical trials has been reported. DSG3-CAART is designed to be a potential treatment for patients with mucosal pemphigus vulgaris (mPV), which is a rare autoimmune blistering disorder that causes painful blisters and sores on mucous membranes leading to severe and sometimes debilitating and life-altering effects. Cabaletta Bio is also pursuing additional pipeline candidates for other B cell mediated disorders including MuSK Myasthenia Gravis (MG) with an IND planned for 2H 2021, mucocutaneous PV, PLA2R positive membranous nephropathy (PMN), and Factor VIII inhibitors.

Uniquely Differentiated. Rapid. Elegant.

At Cabaletta, we are driven by the shared mission of developing a new type of therapy, where patients’ own cells are used to fight disease. We are building a culture grounded in the knowledge that success in the Cabaletta mission lies in the hands of individuals across every aspect of the company. To nurture this, we make an active commitment to the well-being and continuous growth of each person who joins our team. In this way, we are not only working to improve the lives of patients, but of everyone involved. #CabalettaCrew